In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report).

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Bicara Therapeutics (BCAX) opens for trading at $26.25, the company priced an upsized 17.5M share IPO at $18 per share.

Fraser Murray, PhD, CEO, Pheno Therapeutics. Image Credit: Pheno Therapeutics A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to ...

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial Over the past 15 years, the landscape ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are ...

She currently serves on the board of directors of Adcendo, Mbrace Therapeutics and Bicara Therapeutics. Prior to joining TPG in 2021, Dr. Ng was a managing director at Vertex Ventures HC ...

Maze's decision follows a strong 2024 for biotech companies, with firms such as Septerna and Bicara Therapeutics receiving a positive response from investors at their debut. Maze said it earned $9.03 ...